Skip to main content

Table 1 Patient characteristics before and after whole brain radiotherapy

From: Single institutional outcomes of whole brain radiotherapy for metastatic melanoma brain metastases

Variable

Number of patients

% Total

Sex

Male

39

61.9

Female

24

38.1

Year of diagnosis of BM

 < 2011

52

82.5

 ≥ 2011

11

17.5

Number of BM before WBRT

1–4

18

30.5

5–10

32

54.2

 > 10

9

15.3

Unspecified

4

–

CNS progression prior to WBRT

Yes

33

58.9

No

23

41.1

Unknown

7

–

Extracranial metastases

No

20

31.7

Yes

43

68.3

KPS

 ≤ 80

36

57.1

 > 80

27

42.9

ECOG performance status

0

14

22.2

1

33

52.4

2–3

16

25.4

Temozolomide

No

30

47.6

Yes

33

52.4

Interleukin-2

No

53

84.1

Yes

10

15.9

Interferon

No

44

69.8

Yes

19

30.2

BRAF inhibitor

No

55

87.3

Yes

8

12.7

MEK inhibitor

No

60

96.8

Yes

2

3.2

Missing

1

–

Concurrent ipilimumab/nivolumab

No

61

96.8

Yes

2

3.2

Post-WBRT radionecrosis

No

53

84.1

Yes

10

15.9

Post-WBRT intralesional hemorrhage

No

43

68.3

Yes

20

31.7

Post-WBRT memory deficits

No

51

81.0

Yes

12

19.0

Dose of WBRT (Gy)

Mean

32.16

–

Median

30

–

SD

3.59

–

Number of WBRT fractions

Mean

11.71

–

Median

10

–

SD

2.81

–

LDH (before WBRT)

Mean

225

–

Median

179

–

SD

141

–

Age at WBRT (years)

Mean

54.21

–

Median

55.45

–

SD

12.18

–

  1. BM, Brain metastases; WBRT, Whole Brain Radiation Therapy; CNS, Central Nervous System; KPS, Karnofsky Performance Status; ECOG, Eastern Cooperative Oncology Group; Gy, Gray; LDH, lactate dehydrogenase